Kriya Therapeutics raises $270m in Series C funding round
The company intends to use the funds to advance its pipeline and scaling of its platforms.

The company intends to use the funds to advance its pipeline and scaling of its platforms.
The company intends to commence a Phase I/II trial of EDIT-301 in transfusion-dependent beta thalassemia patients this year.
The EC approval is based on the international Phase II ELARA clinical trial of Kymriah.
Although some countries are moving ahead, the use of CAR-T therapies in the region remains uneven.
BySafety and tolerability will be the primary outcome measures in the monotherapy and combination phases of Phase I/II trial.
Current Cytovia co-founder, chairman and CEO Dr Daniel Teper will lead the combined company.
Under the deal, Porton will offer services to develop breakthrough cell therapies of Sinorda.
A $1 million price point is not out of question for bluebird bio’s beta thalassemia therapy if long-term benefits are…
By